Comparative Biosciences, Inc. (CBI), a preclinical contract research organization (CRO), provides expertise in discovery toxicology services. Discovery toxicology is a key process in the identification, characterization, and selection of new products for development. CBI offers a number of fast, inexpensive research programs designed to assess, characterize, and rank new molecules for toxicity and efficacy, and to assist in the selection process. For early discovery toxicology projects, CBI also offers a range of nonGLP exploratory toxicity studies for early assessment of molecules including single dose, multiple dose, and targeted studies, as well as directed or investigative toxicology.